DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

Thumbnail
View / Open Files
Authors
Kizhakeyil, Atish
Zaini, Nurmahirah Binte Mohammed
Poh, Zhi Sheng
Wong, Brandon Han Siang
Loh, Xinpeng
Ng, Aik Seng
Low, Zun Siong
Publication Date
2021-10-16
Journal Title
Mol Cancer
ISSN
1476-4598
Publisher
Springer Science and Business Media LLC
Volume
20
Issue
1
Pages
134
Language
eng
Type
Article
This Version
VoR
Physical Medium
Electronic
Metadata
Show full item record
Citation
Kizhakeyil, A., Zaini, N. B. M., Poh, Z. S., Wong, B. H. S., Loh, X., Ng, A. S., Low, Z. S., et al. (2021). DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.. Mol Cancer, 20 (1), 134. https://doi.org/10.1186/s12943-021-01437-0
Abstract
Non-Hodgkin a diverse group of malignancies, encompassing the common difuse large B-cell lymphoma (DLBCL) to the rarer T-cell lymphomas. Chemoresistance is a major barrier to treatment and the mechanisms through which it occurs are incompletely understood [1]. Although eforts are made to target frequently dysregulated pathways in NHL subtypes, these diseases still evolve into aggressive forms resistant even to newer therapies [2].
Sponsorship
This research was supported, in part, by Start-Up Grant to NKV provided by Lee Kong Chian School of Medicine, Nanyang Technological University Singapore (L0412290), the Singapore Ministry of Education (MOE) under its MOE Academic Research Fund (AcRF) Tier 2 Grant (MOE2017-T2–2-004), and the National Research Foundation Singapore under its Open Fund Large Collaborative Grant (OFLCG18May-0028) and administered by the Singapore Ministry of Health’s National Medical Research Council (NMRC). N.F.G. acknowledges funding support from the Singapore Ministry of Health’s National Medical Research Council under its NMRC of Singapore Transition Award (NMRC/TA/0051/2016), Kay Kendall Leukaemia Fund Junior Clinical Research Training Fellowship (KKL649) and the Addenbrooke’s Charitable Trust Research Training Fellowship. D.H. was supported by the Medical Research Council (MR/M008584/1) and Blood Cancer UK and receives core funding from Wellcome (203151/Z/16/Z) and MRC to the Wellcome-MRC Cambridge Stem Cell Institute and from the CRUK Cambridge Centre (A25117). A.K. and Z.S.P. were provided with PhD fellowship by Lee Kong Chian School of Medicine, Nanyang Technological University Singapore. B.H.S.W. was provided with PhD fellowship by HealthTech NTU, Nanyang Technological University Singapore.
Funder references
Wellcome Trust (203151/Z/16/Z)
Medical Research Council (MR/M008584/1)
Cancer Research UK (A25117)
Identifiers
External DOI: https://doi.org/10.1186/s12943-021-01437-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/329796


Rights
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International